Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Operations: 2020-2025

Historic Cash from Operations for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $39.7 million.

  • Mirum Pharmaceuticals' Cash from Operations rose 896.01% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.7 million, marking a year-over-year increase of 3748.33%. This contributed to the annual value of $10.3 million for FY2024, which is 114.55% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Cash from Operations stood at $39.7 million for Q3 2025, which was up 229.58% from $12.0 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Cash from Operations high stood at $39.7 million for Q3 2025, and its period low was -$40.2 million during Q2 2021.
  • Its 3-year average for Cash from Operations is -$987,182, with a median of -$3.8 million in 2024.
  • Per our database at Business Quant, Mirum Pharmaceuticals' Cash from Operations slumped by 136.55% in 2021 and then skyrocketed by 896.01% in 2025.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Cash from Operations stood at -$33.1 million in 2021, then fell by 3.39% to -$34.3 million in 2022, then soared by 51.51% to -$16.6 million in 2023, then surged by 69.50% to -$5.1 million in 2024, then skyrocketed by 896.01% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $12.0 million for Q2 2025, and -$2.0 million during Q1 2025.